Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipratropium/Levosalbutamol FDC vs Free Combination in COPD
NCT04446637Phase 3Withdrawn
- Sponsor
- Neutec Group
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial in chronic obstructive pulmonary disease (COPD) comparing Ipratropium/Levosalbutamol FDC with Salbutamol + Ipratropium Free Combo (2 arms). Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve (0-8 hours). Planned start Sep 2021; status: withdrawn.
02
Drugs
levalbuterolipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04446637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446637.